Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (220)	12/12/2000 10:32:34 AM
From: keokalani'nui	Read Replies (2) \| Respond to of 1784

Trickle may have to travel. For immediate release EVOTEC OAI Announces Collaboration with Olympus Hamburg, December 12, 2000 – EVOTEC BioSystems AG (EVOTEC OAI) (Neuer Markt: EVT) today announced that they intend to develop their next generation of diagnostic analyzers with Olympus Optical Co. Ltd., Tokyo, Japan. These instruments will be based on EVOTEC OAI’s proprietary single molecule detection technologies and will be used in research and diagnostic testing (e.g. genotyping). EVOTEC OAI’s proprietary detection system enables testing in minute sample volumes. Approximately 50 instruments employing this detection system are already installed worldwide at EVOTEC OAI’s drug discovery partners, its development partners for diagnostic tests and at the Company’s own research facilities. This agreement represents an important strategic milestone for the establishment and future growth of EVOTEC OAI’s instrument business by leveraging the Company’s novel detection technologies, in particular for diagnostic applications. EVOTEC OAI offers the full range of high-value added products and services required to discover and develop drugs more effectively and efficiently. By integrating accelerated methods in biology, chemistry and screening, the Company has established a unique position as a one-stop-shop for all the critical elements in the drug discovery research and development process from gene to clinical development. Approximately 500 people are based in Hamburg, Germany and Abingdon, U.K. EVOTEC OAI already has close links with many of the leading companies in the pharmaceutical and biotechnology industries, including Novartis, Pfizer, SmithKline Beecham, Aventis, Pharmacia/Sugen, Bayer, BMS, Roche, Amgen, Biogen, Vertex, Serono and Immunex. The new Company’s shares are listed on the Neuer Markt of the Frankfurt Stock Exchange. (Background Information: On July 31, 2000, EVOTEC, a German registered public company, and OAI, a U.K. registered public company, announced their intention to merge. This merger became unconditional on 29th September 2000. OAI formally de-listed from the London Stock Exchange on 1st December 2000.)